ADAMTS13 and thrombotic thrombocytopenic purpura: The first in 2017 reported on four competing testing strategies for a patient suspected of having immune TTP: (1) send-out ADAMTS13 activity versus (2) in-house ADAMTS13 activity versus (3) PLASMIC clinical score application followed by send-out ADAMTS13 testing for intermediate-to-high risk PLASMIC-scoring patients versus (4) PLASMIC clinical score application followed by in-house ADAMTS13 testing for intermediate-to-high risk PLASMIC-scoring patients [83].